Physician profile
Dwayne Eldrich Friday
NPI 1619101557
$10,101.09
in general payments reported to CMS, 2019-2025
41 companies · $2,634 in 2025
The $2,634 reported for 2025 was more than what 95% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $504 · 2020: $248 · 2021: $536 · 2022: $1,226 · 2023: $2,318 · 2024: $2,635 · 2025: $2,634.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,515 · Education: $72.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,515.38 |
| Education | $72.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,261.23 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Bayer Healthcare Pharmaceuticals INC. | $1,057.15 | 2021-2025 | |
| Lilly USA, LLC | $896.63 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $827.23 | 2019-2025 | Xifaxan |
| Amgen INC. | $549.97 | 2019-2025 | Otezla, Repatha, Otezla |
| Novo Nordisk INC | $542.66 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $489.16 | 2019-2025 | Jardiance |
| Glaxosmithkline, LLC. | $484.59 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Abbvie INC. | $421.67 | 2022-2025 | |
| Janssen Pharmaceuticals, INC | $256.89 | 2019-2024 | Xarelto |
| Pfizer INC. | $233.00 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $208.31 | 2019-2025 | |
| Ardelyx, INC. | $208.14 | 2025 | Ibsrela |
| Medtronic, INC. | $186.51 | 2022-2025 | Corevalve Evolut R, Minimed 780g |
| Astellas Pharma US INC | $162.92 | 2019-2025 | Veozah, Myrbetriq |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dwayne Friday listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.